Concord Biotech facility passes NAFDAC inspection

Concord Biotech Limited has successfully completed an inspection by the National Agency for Food and Drug Administration (NAFDAC) at its Oral Solid Dosage (OSD) Unit-2 facility, located in Valthera, Gujarat. The inspection, which took place from October 6, 2025, to October 7, 2025, marks a key achievement for the company.

The successful completion of this NAFDAC inspection highlights Concord Biotech's commitment to maintaining high standards of quality, safety, and regulatory compliance across its operations. The company emphasized its dedication to excellence and its continued focus on meeting the stringent requirements set by global regulatory authorities.

This announcement was made on October 8, 2025, and reported by Hina Patel, company secretary and compliance officer. The development reinforces Concord Biotech's position in adhering to international pharmaceutical standards.